ReviewHepatology international2017
Non-invasive diagnosis of hepatic steatosis.
Review in Hepatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis.Lipids in health and disease · 2022Pooled it
- Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.Molecules (Basel, Switzerland) · 2021Pooled it
- Efficacy of Dietary Supplements to Reduce Liver Fat.Nutrients · 2020Pooled it
- Trial
- Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults.International journal of medical sciences · 2019Trial
- Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.Nature reviews. Gastroenterology & hepatology · 2026Review
- Association of AGAHR with metabolic dysfunction-associated steatotic liver disease (MASLD).Hormones (Athens, Greece) · 2026Article
- Article
- Applications of Artificial Intelligence and Smart Devices in Metabolic Dysfunction-associated Steatotic Liver Disease.Journal of clinical and translational hepatology · 2026Article
- From Pathophysiological Consensus to Integrative Potential: A Comprehensive Narrative Review of Traditional Chinese Medicine Interventions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Future Directions.International journal of general medicine · 2026Review
- Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.The Cochrane database of systematic reviews · 2025Article
- Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.Frontiers in medicine · 2025Article
- Nine anthropometric indices predict hepatic steatosis and assess liver health in adolescents: a population-based study.Frontiers in pediatrics · 2025Article
- Predicting Nonalcoholic Fatty Liver Disease in Obese Populations with 3D Body Scans.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2024Article
- Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003-2018.Lipids in health and disease · 2024Article
- Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.Clinical and molecular hepatology · 2024Review
- Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study.Clinical and molecular hepatology · 2023Article
- Article
- Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review.Clinical liver disease · 2023Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-invasive diagnosis and quantification of hepatic steatosis rely on two different but complementary approaches: biomarkers or imaging techniques, either ultrasound-based such as liver ultrasonography and controlled attenuation parameter (CAP), or computed tomography (CT) and magnetic resonance imaging (MRI). Scores for the detection of steatosis have not gained much popularity in clinical practice so far. CAP, using the M probe, is the most promising technique but needs to be implemented with the XL probe and compared to ultrasound that, despite its limitations, remains the most widely used method. CT, owing to its low sensitivity and the fact that it involves a potential radiation hazard, is inappropriate. Finally, proton density fat fraction measurement by MRI is currently the most accurate and sensitive imaging method, simpler and more practical than magnetic resonance spectroscopy, but restricted, up to now, just to research and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.